Management of antiplatelet therapy in patients undergoing neuroendovascular procedures
- 1 October 2018
- journal article
- review article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 129 (4), 890-905
- https://doi.org/10.3171/2017.5.jns162307
Abstract
Neuroendovascular techniques for treating cerebral aneurysms and other cerebrovascular pathology are increasingly becoming the standard of care. Intraluminal stents, aneurysm coils, and other flow diversion devices typically require concomitant antiplatelet therapy to reduce thromboembolic complications. The variability inherent with the pharmacodynamic response to common antiplatelet agents such as aspirin and clopidogrel complicates optimal selection of antiplatelet agents by clinicians. This review serves to discuss the literature related to antiplatelet use in neuroendovascular procedures and provides recommendations for clinicians on how to approach patients with variable response to antiplatelet agents, particularly clopidogrel.Keywords
This publication has 69 references indexed in Scilit:
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 UpdateClinical Pharmacology & Therapeutics, 2013
- Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment–Elevation Myocardial InfarctionCirculation: Cardiovascular Interventions, 2012
- Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional proceduresJournal of NeuroInterventional Surgery, 2012
- Do Clopidogrel Nonresponders Have an Increased Risk of Adverse Events during Supra-Aortal Angioplasty and Stenting?Stroke Research and Treatment, 2012
- PharmGKB summaryPharmacogenetics and Genomics, 2012
- Optimal Use of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Patients Undergoing Percutaneous Coronary InterventionsDrugs, 2011
- Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary InterventionCirculation, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel TherapyClinical Pharmacology & Therapeutics, 2011
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel TreatmentThe New England Journal of Medicine, 2010
- Stability of an extemporaneously prepared clopidogrel oral suspensionAmerican Journal of Health-System Pharmacy, 2010